Attention Deficit-Hyperactivity DisorderTLR;NCT04038073
TLR Polymorphism, ASO and Beta-hemolytic Group A Streptococcus Infections in ADHD: an Observational Study
An observational study of Attention Deficit-Hyperactivity Disorder, run by University of Turin, Italy at 1 site in Italy.
Trial summary
The aim of this observational cross-sectional study is to evaluate the streptococcal infection (clinical history, ASLO title and anti-DNAse title B) and autoimmunity (ABGA antibodies) in a sample of 100 adult patients diagnosed with ADHD (ie in patients in whom the disorder is permanent). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Attention Deficit-Hyperactivity Disorder
- What is being tested?
- Antistreptolysin O Test, Anti-Deoxyribonuclease B and TLR, MyD88, IRAK-4 polymorphism
- How many people
- 100 participants
- Where
- 1 siteItaly
- Study dates
- 3 Jun 2019to 1 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Participants with ADHD disgnosis (according to DSM-5 criteria) will be recruited for a single blood sample.
Who may be able to join
- diagnosis of ADHD according to DSM-5 criteria
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
AOU San Luigi Gonzaga di Orbassano
Orbassano, Torino, 10043
Francesco Oliva, 3335613155, francesco.oliva@unito.it
About this study
Official title: Toll-Like Receptor Polymorphism, Antinuclear Antibodies and Beta-hemolytic Group A Streptococcus Infections in Attention-Deficit/Hyperactivity Disorder: an Observational Study
The aim of this observational cross-sectional study is to evaluate the streptococcal infection (clinical history, ASLO title and anti-DNAse title B) and autoimmunity (ABGA antibodies) in a sample of 100 adult patients diagnosed with ADHD (ie in patients in whom the disorder is permanent). Another objective will be to evaluate the frequency and types of genetic alterations of innate immunity (TLR polymorphisms, MyD88, IRAK-4) that can determine an infantile susceptibility to gram positive infections (ie S. pyogenes, S. pneumoniae, S. aureus) and the possible relationship between these elements, also in relation to comorbidity with other ABGA-related pathologies, to identify a possible pathogenetic immune mechanism of ADHD. Prevalence data will be obtained on an outpatient ADHD population for previous (history) and recent streptococcal infection (ASLO and Anti-DNAsiB), for the detection of ABGA and for the co-presence of other ABGA-related pathologies. By comparing the subgroups obtained by dividing the results on the basis of the positive infectious history, anti-streptococcus, autoantibody and comorbidity titers, it will be possible to assess whether the elevation of the ABGA titer is only linked to the previous/current infection ("infectious" group) or if there is a subpopulation of ADHD patients presenting pathological elevation of ABGA titers in the absence of infectious pictures ("immune" group). Furthermore, it is expected that the comparison of the descriptive polymorphisms TLR, MyD88 and IRAK-4 between the "infectious" and "immune" group may show a predisposition in subjects of the "immune" group.
Read the detailed description
Attention Deficit / Hyperactivity Disorder (ADHD) is the most widespread neurodevelopmental disorder (prevalence 3-7% in preschool age) and is characterized by persistent inattention and / or hyperactivity-impulsivity which results in significant impairment in at least two areas of operation (usually scholastic / working and relational) with consequent impact even on the child's self-esteem. It is estimated that one-third of children with ADHD continue to be affected in adulthood and that around one-third have remission of symptoms with persisting changes in functioning and development of psychiatric disorders in adulthood (eg anxiety disorders mood and personality). The pathogenetic model of ADHD is still poorly characterized: several biological, psychological and environmental causes have been identified that would seem to interact in a complex way in determining the pathology. Several studies have hypothesized and confirmed an association between streptococcal infections, increased titer of antibodies to the basal nuclei (ABGA), different neurological and psychiatric disorders (eg, Sydenham chorea, Tic Disorders, Obsessive-Compulsive Disorder) and ADHD. ADHD is diagnosed in 40% of autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) and Sydenham Korea and a temporal connection between onset / exacerbation of ADHD and pharyngeal streptococcal infection has been described in literature. High titers of anti-streptococcal antibodies and larger size of putamen and pallidum were found in ADHD patients. However, the permanence of symptoms ADHD at a distance from streptococcal infection has led to hypothesize, as already done for PANDAS and Sydenham Korea, a miminking mechanism with consequent cross-reactivity towards host tissues that would support an autoimmune disorder characterized by the production of ABGA.
According to some authors, therefore, ADHD and other ABGA-related neurological and psychiatric disorders (eg, Sydenham Korea, Tic Disorders, Obsessive-Compulsive Disorder) would be different phenotypic manifestations of a common immunological disorder affecting the nuclei of the base, triggered from group A beta-hemolytic streptococcus. The search for ABGA in ADHD patients with Tic Disorders and Obsessive-Compulsive Disorder has largely confirmed this hypothesis, however, the finding of ABGA titres in ADHD patients without comorbidities with other ABGA-related disorders is still controversial. A first study found no differences significant in terms of ABGA positivity frequency among ADHD patients without ABGA related disorders and controls while a more recent study conducted confirmed that children with ADHD without ABGA-related disorders are more frequently positive for ABGA than the control group (30% vs 4.8%; χ2 = 4.33; p = 0.04) and that, among these, those with Anti-Streptolysinic Title (ASLO) show significantly higher percentages of ABGA positivity (χ2 = 10.95; p <.001). On the other hand, greater susceptibility by ADHD patients to contracting streptococcal infections was confirmed by the finding of significantly higher titers of ASLO and anti-DNAse B in ADHD patients.
The predisposition to infections and the high familiarity of ADHD (90% of cases have at least one affected parent), suggest an immune pathogenetic mechanism based on a genetic predisposition.
Although several studies have established, in an inconclusive way, a relationship between ADHD and some regulatory genes, the major histocompatibility complex (MHC), such as HLA-DR4, HLA-DRB1 and C4B, to date no one has yet evaluated the role of Toll-type receptor (TLR) genes, which are more responsible for innate immunity, ie the recognition of pathogenic structural molecules. In particular, some variants of the TLR genes could affect the immune response to strepotococcus or other pathogens, favoring damage to the nuclei of the base which would in turn lead to ADHD symptoms. Recently, an association between susceptibility to serious or recurrent infections from group A beta-hemolytic streptococcus, Streptococcus pneumoniae, Haemophilus influenza and particular polymorphisms of TLR2, TLR4 and TLR9 has been demonstrated. The altered functioning consequent to these TLR polymorphisms could explain both the vulnerability to certain types of pathogens responsible for lesions to the central nervous system (among which the most studied so far is Group A beta-hemolytic streptococcus), whether the incongruous or excessive immune activation even in the absence of contact with pathogens producing autoantibodies against the nerve structures of the base nuclei.
- Conditions
- Attention Deficit-Hyperactivity Disorder
- Being tested
- Antistreptolysin O Test, Anti-Deoxyribonuclease B, TLR, MyD88, IRAK-4 polymorphism, Anti-Basal Ganglia Antibody
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antistreptolysin O TestDiagnostic test
Also called ASO
Test to evaluate of any histories of streptococcal infections
Anti-Deoxyribonuclease BDiagnostic test
Also called Anti-DNase B
Test to evaluate of any histories of streptococcal infections
TLR, MyD88, IRAK-4 polymorphismDiagnostic test
Test to evaluate of the frequency and types of genetic alterations of innate immunity
Anti-Basal Ganglia AntibodyDiagnostic test
Also called ABGA
Test to evaluate the autoimmune component
| Study group | Role | What they receive |
|---|---|---|
| ADHD | Attention Deficit/Hyperactivity Disorder Receives: Diagnostic Test: Antistreptolysin O Test; Diagnostic Test: Anti-Deoxyribonuclease B; Diagnostic Test: TLR, MyD88, IRAK-4 polymorphism; Diagnostic Test: Anti-Basal Ganglia Antibody |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of Antistreptolysin O and Anti-Deoxyribonuclease B
diagnostic blood sample test to measure streptococcal infections
Measured: up to 1 year till the end of the study
Measurement of TLR, MyD88, IRAK-4 polymorphism
diagnostic blood sample test to measure genetic alterations of innate immunity
Measured: up to 1 year till the end of the study
Measurement of Anti-Basal Ganglia Antibody
diagnostic blood sample test to assess the autoimmune component
Measured: up to 1 year till the end of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2019
- Study start3 Jun 2019
- Primary completion30 Jun 2020 (estimated)
- Study completion1 Dec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Attention Deficit-Hyperactivity DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Turin, Italy
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Francesco Oliva, University of Turin, Italy
- Investigators
- Francesco Oliva, Principal investigator, University of Turin, Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04038073
- Sponsor's protocol ID
- ADHD_TLR
- Acronym
- TLR;
- Status last verified
- Mar 2020
- First submitted
- 24 Jul 2019
- Last updated
- 25 Mar 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Toll-Like Receptor Polymorphism, Antinuclear Antibodies and Beta-hemolytic Group A Streptococcus Infections in Attention-Deficit/Hyperactivity Disorder: an Observational Study
- ClinicalTrials.gov ID
- NCT04038073
- Acronym / sponsor ID
- TLR; / ADHD_TLR
- Conditions
- Attention Deficit-Hyperactivity Disorder
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of Turin, ItalyUniversity, hospital or other
- Study start
- 3 Jun 2019 (actual)
- Primary completion
- 30 Jun 2020 (estimated)
- Study completion
- 1 Dec 2020 (estimated)
- First posted
- 30 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this observational cross-sectional study is to evaluate the streptococcal infection (clinical history, ASLO title and anti-DNAse title B) and autoimmunity (ABGA antibodies) in a sample of 100 adult patients diagnosed with ADHD (ie in patients in whom the disorder is permanent). Another objective will be to evaluate the frequency and types of genetic alterations of innate immunity (TLR polymorphisms, MyD88, IRAK-4) that can determine an infantile susceptibility to gram positive infections (ie S. pyogenes, S. pneumoniae, S. aureus) and the possible relationship between these elements, also in relation to comorbidity with other ABGA-related pathologies, to identify a possible pathogenetic immune mechanism of ADHD. Prevalence data will be obtained on an outpatient ADHD population for previous (history) and recent streptococcal infection (ASLO and Anti-DNAsiB), for the detection of ABGA and for the co-presence of other ABGA-related pathologies. By comparing the subgroups obtained by dividing the results on the basis of the positive infectious history, anti-streptococcus, autoantibody and comorbidity titers, it will be possible to assess whether the elevation of the ABGA titer is only linked to the previous/current infection ("infectious" group) or if there is a subpopulation of ADHD patients presenting pathological elevation of ABGA titers in the absence of infectious pictures ("immune" group). Furthermore, it is expected that the comparison of the descriptive polymorphisms TLR, MyD88 and IRAK-4 between the "infectious" and "immune" group may show a predisposition in subjects of the "immune" group.
Detailed description
Attention Deficit / Hyperactivity Disorder (ADHD) is the most widespread neurodevelopmental disorder (prevalence 3-7% in preschool age) and is characterized by persistent inattention and / or hyperactivity-impulsivity which results in significant impairment in at least two areas of operation (usually scholastic / working and relational) with consequent impact even on the child's self-esteem. It is estimated that one-third of children with ADHD continue to be affected in adulthood and that around one-third have remission of symptoms with persisting changes in functioning and development of psychiatric disorders in adulthood (eg anxiety disorders mood and personality). The pathogenetic model of ADHD is still poorly characterized: several biological, psychological and environmental causes have been identified that would seem to interact in a complex way in determining the pathology. Several studies have hypothesized and confirmed an association between streptococcal infections, increased titer of antibodies to the basal nuclei (ABGA), different neurological and psychiatric disorders (eg, Sydenham chorea, Tic Disorders, Obsessive-Compulsive Disorder) and ADHD. ADHD is diagnosed in 40% of autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) and Sydenham Korea and a temporal connection between onset / exacerbation of ADHD and pharyngeal streptococcal infection has been described in literature. High titers of anti-streptococcal antibodies and larger size of putamen and pallidum were found in ADHD patients. However, the permanence of symptoms ADHD at a distance from streptococcal infection has led to hypothesize, as already done for PANDAS and Sydenham Korea, a miminking mechanism with consequent cross-reactivity towards host tissues that would support an autoimmune disorder characterized by the production of ABGA.
According to some authors, therefore, ADHD and other ABGA-related neurological and psychiatric disorders (eg, Sydenham Korea, Tic Disorders, Obsessive-Compulsive Disorder) would be different phenotypic manifestations of a common immunological disorder affecting the nuclei of the base, triggered from group A beta-hemolytic streptococcus. The search for ABGA in ADHD patients with Tic Disorders and Obsessive-Compulsive Disorder has largely confirmed this hypothesis, however, the finding of ABGA titres in ADHD patients without comorbidities with other ABGA-related disorders is still controversial. A first study found no differences significant in terms of ABGA positivity frequency among ADHD patients without ABGA related disorders and controls while a more recent study conducted confirmed that children with ADHD without ABGA-related disorders are more frequently positive for ABGA than the control group (30% vs 4.8%; χ2 = 4.33; p = 0.04) and that, among these, those with Anti-Streptolysinic Title (ASLO) show significantly higher percentages of ABGA positivity (χ2 = 10.95; p <.001). On the other hand, greater susceptibility by ADHD patients to contracting streptococcal infections was confirmed by the finding of significantly higher titers of ASLO and anti-DNAse B in ADHD patients.
The predisposition to infections and the high familiarity of ADHD (90% of cases have at least one affected parent), suggest an immune pathogenetic mechanism based on a genetic predisposition.
Although several studies have established, in an inconclusive way, a relationship between ADHD and some regulatory genes, the major histocompatibility complex (MHC), such as HLA-DR4, HLA-DRB1 and C4B, to date no one has yet evaluated the role of Toll-type receptor (TLR) genes, which are more responsible for innate immunity, ie the recognition of pathogenic structural molecules. In particular, some variants of the TLR genes could affect the immune response to strepotococcus or other pathogens, favoring damage to the nuclei of the base which would in turn lead to ADHD symptoms. Recently, an association between susceptibility to serious or recurrent infections from group A beta-hemolytic streptococcus, Streptococcus pneumoniae, Haemophilus influenza and particular polymorphisms of TLR2, TLR4 and TLR9 has been demonstrated. The altered functioning consequent to these TLR polymorphisms could explain both the vulnerability to certain types of pathogens responsible for lesions to the central nervous system (among which the most studied so far is Group A beta-hemolytic streptococcus), whether the incongruous or excessive immune activation even in the absence of contact with pathogens producing autoantibodies against the nerve structures of the base nuclei.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ADHD | – | Diagnostic Test: Antistreptolysin O Test, Diagnostic Test: Anti-Deoxyribonuclease B, Diagnostic Test: TLR, MyD88, IRAK-4 polymorphism, Diagnostic Test: Anti-Basal Ganglia AntibodyAttention Deficit/Hyperactivity Disorder |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Participants with ADHD disgnosis (according to DSM-5 criteria) will be recruited for a single blood sample.
Key inclusion criteria (1 listed)
- diagnosis of ADHD according to DSM-5 criteria
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antistreptolysin O TestAlso: ASOTest to evaluate of any histories of streptococcal infections | Diagnostic test | ADHD |
| Anti-Deoxyribonuclease BAlso: Anti-DNase BTest to evaluate of any histories of streptococcal infections | Diagnostic test | ADHD |
| TLR, MyD88, IRAK-4 polymorphismTest to evaluate of the frequency and types of genetic alterations of innate immunity | Diagnostic test | ADHD |
| Anti-Basal Ganglia AntibodyAlso: ABGATest to evaluate the autoimmune component | Diagnostic test | ADHD |
Primary outcome
Measurement of Antistreptolysin O and Anti-Deoxyribonuclease B
Time frame: up to 1 year till the end of the study
diagnostic blood sample test to measure streptococcal infections
Measurement of TLR, MyD88, IRAK-4 polymorphism
Time frame: up to 1 year till the end of the study
diagnostic blood sample test to measure genetic alterations of innate immunity
Measurement of Anti-Basal Ganglia Antibody
Time frame: up to 1 year till the end of the study
diagnostic blood sample test to assess the autoimmune component
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Mar 2020.
- Individual participant dataSharing planned: No
Related trials for Attention Deficit-Hyperactivity Disorder
RecruitingObservational study
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy
Irritability, Disruptive Mood Dysregulation Disorder
RecruitingPhase 2
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Attention Deficit Disorder With Hyperactivity (ADHD)
RecruitingObservational study
Pharmacogenomics of Stimulant Treatment Response
Attention-Deficit/ Hyperactivity Disorder (ADHD)
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Francesco Oliva principal investigator
University of Turin, Italy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Attention Deficit-Hyperactivity Disorder, run by University of Turin, Italy at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Francesco Oliva (3335613155, francesco.oliva@unito.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of Antistreptolysin O and Anti-Deoxyribonuclease B (time frame: up to 1 year till the end of the study). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2020.